APP Obtains FDA Approval For Penicillin G Potassium For Injection

APP Pharmaceuticals (APP) has received approval from the FDA to market Penicillin G Potassium for Injection, USP, in two dosage strengths.

Penicillin G is used to treat a wide variety of bacterial infections, including pneumococcal infections, streptococcal infections, staphylococcal infections, diphtheria, meningitis, clostridial infections and anthrax.

According to the Center for Disease Control and Prevention (CDC), Penicillin G is the treatment of choice for congenital syphilis, neurosyphilis and prophylaxis of intrapartum group B streptococcus.

Thomas Silberg, president and CEO of APP, said: “The addition of Penicillin G further strengthens APP’s broad anti-infective portfolio. We are looking forward to making this potentially life-saving antibiotic available to patients throughout the US.”